MediPharm Labs - MEDIF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.18
  • Forecasted Upside: 188.78 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.06
+0 (0.00%)

This chart shows the closing price for MEDIF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MediPharm Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDIF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDIF

Analyst Price Target is $0.18
▲ +188.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MediPharm Labs in the last 3 months. The average price target is $0.18, with a high forecast of $0.25 and a low forecast of $0.10. The average price target represents a 188.78% upside from the last price of $0.06.

This chart shows the closing price for MEDIF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in MediPharm Labs. This rating has held steady since April 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/17/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$0.20 ➝ C$0.10
4/4/2022Canaccord Genuity GroupLower TargetHold ➝ HoldC$0.35 ➝ C$0.20
4/1/2022Alliance Global PartnersLower TargetC$0.35 ➝ C$0.25
11/16/2021Alliance Global PartnersDowngradeBuy ➝ Neutral
8/16/2021Alliance Global PartnersLower TargetBuy ➝ BuyC$1.00 ➝ C$0.80
5/18/2021Alliance Global PartnersLower TargetBuyC$1.25 ➝ C$1.00
4/16/2021BMO Capital MarketsInitiated CoverageMarket Perform
11/16/2020Roth CapitalLower TargetBuy$2.00 ➝ $1.00
11/2/2020Alliance Global PartnersInitiated CoverageBuy
6/19/2020MackieDowngradeHold$1.75
6/18/2020Pi FinancialDowngradeHold$1.75
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.85 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/8/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
MediPharm Labs logo
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
Read More

Today's Range

Now: $0.06
Low: $0.05
High: $0.07

50 Day Range

MA: $0.06
Low: $0.05
High: $0.07

52 Week Range

Now: $0.06
Low: $0.04
High: $0.20

Volume

41,633 shs

Average Volume

144,787 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MediPharm Labs?

The following sell-side analysts have issued stock ratings on MediPharm Labs in the last year: Alliance Global Partners, and Canaccord Genuity Group Inc..
View the latest analyst ratings for MEDIF.

What is the current price target for MediPharm Labs?

2 Wall Street analysts have set twelve-month price targets for MediPharm Labs in the last year. Their average twelve-month price target is $0.18, suggesting a possible upside of 188.8%. Alliance Global Partners has the highest price target set, predicting MEDIF will reach $0.25 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $0.10 for MediPharm Labs in the next year.
View the latest price targets for MEDIF.

What is the current consensus analyst rating for MediPharm Labs?

MediPharm Labs currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEDIF will outperform the market and that investors should add to their positions of MediPharm Labs.
View the latest ratings for MEDIF.

What other companies compete with MediPharm Labs?

How do I contact MediPharm Labs' investor relations team?

MediPharm Labs' physical mailing address is 151 John Street, Barrie, ON L4N. The company's listed phone number is (705) 719-7425. The official website for MediPharm Labs is www.medipharmlabs.com. Learn More about contacing MediPharm Labs investor relations.